CURRICULUM VITAE

Rui Tato Marinho, M.D., PhD, date of birth: 6th January 1958, Lisbon, Portugal.

Place of work: Liver Unit, Department of Gastroenterology and Hepatology (Director Prof. José Velosa), University Hospital of Santa Maria, Lisbon, Portugal. Working for 40 hours/week with exclusive dedication.Recognised Centre for Training in Gastroenterology and Hepatology by the European Board of Gastroenterology and Hepatology (2009).

Medical School: Faculdade Ciências Médicas, Universidade Nova Lisboa, 1982. Graduation 17/20. Auxiliary Professor at 30%.

PhD Thesis: T-cell immunity in pathogenesis of hepatitis C chronic infection. Contribution for a vaccine development. Medical School of Lisbon, Hospital S. Maria, Universidade Lisboa. Graduation with unanimity 20/20, 2002.

Teaching activity: since 1987, in Medical School of Lisbon, 1st, 3th, 5th and 6th year.

Specialist in Gastroenterology, Subspecialist in Hepatology by the Portuguese Medical Associationof Portugal, number 26118

1986-1991: Completed specialization in Gastroenterology, Hospital S. Maria. 1992-1994: Course of special studies in Hepatology, Liver Unit, Hospital S. Maria. 2005: Recognized as subspecialist in Hepatology by the Portuguese Medical Association

Actual Positions: Member of Scientific Committee for the National Strategy for the Approach of Viral Hepatitis (Ministry of

Health, Direção-Geral da Saúde), since May 2014. Coordinator of the guidelines for the new DAAs - 2015.

Vice-President of Portuguese Society of Gastroenterology PSG, 2013-2017. Editor of PSG News (2013-2015), having now being published around 100 issues. Editor-in-chief of Acta Médica Portuguesa (Portuguese Medical Association), 2011 – 2016. The official

journal of the Portuguese Medical Association (Ordem dos Médicos), indexed in Pubmed /Medline and ISI Web of Science (first year Impact factor in 2010, increasing in the last four years from 0,091 to 0.360). Presence in web 2.0 (Facebook, Twitter, Wikipedia). Acta Médica Portuguese in the only general medical portuguese journal indexed, receiving now around 850 submissions/year.

Member of Pedagogic Committee of Medical School of Lisbon, 2014-2017. Member of Scientific Commission of Masters in Palliative Care of Medical School of Lisbon, since 2014.

Past Positions: Coordinator of Consultive Panel for Hepatitis C Treatment for INFARMED (National Authority of

Medicines and Health Products), May 2014 – January 2015 (Ministry of Health). President of College of Hepatology for the Portuguese Medical Association, 2012-2015. Editor-in-chief of the Portuguese Journal of Gastroenterology, 2009 – 2011. Member of Editorial Board

1997 – 2005. Portuguese Society of Gastroenterology: General-Secretary: 2005–2007. Member of the Board since

2001. Portuguese Association for Study of Liver: President 2007–2009, General-Secretary 1993-1997. Webmaster of the site of the Portuguese Society of Gastroenterology (www.spg.pt), 2000–2007.

1

President of the Editorial Commission of Portuguese Society of Gastroenterology, 2013-2015. President of the National Centre of Data Registry in Gastroenterology, 2006 – 2010. Member of the Ethics Commission of “Instituto Droga e Toxicodependência”, 2006.

Clinical ActivityOutpatient Clinic (2073 consultations in year 2014: general hepatology, therapy of viral hepatitis), Inpatient Clinic (Liver Unit), Emergency (Intensive Care Unit of Gastroenterology and Hepatology, Department of Gastroenterology). Regular performance of liver biopsy, Fibroscan®. Coordinator of the outpatient Department of Gastroenterology of Hospital Santa Maria (35 doctors, 23.000 Consultations/year) since October 2008.

PhD thesis co-orientation and/or researchHepatitis C

David Barreira (Psychology, Medical School of Lisbon, Psychobiological Characterization of Depression in Hepatitis C),

João Paulo Cruz (Pharmacist, in collaboration with Faculty of Pharmacy, Lisbon, Impact of Pharmacogenetics on the Population Pharmacokinetics of Antiretroviral drugs in HIV/HCV and/or HBV co-infected patients).

Rute Marcelino (Biologist). B cells of memory: a new approach to define new epitopes in the neutralization of hepatitis C virus. Instituto de Higiene e Medicina Tropical, Unidade de Microbiologia Médica. Collaboration with com Rockefeller University, Laboratory of Virology and Infectious Disease (Charles Rice). Fundação para a Ciência e Tecnologia – ref. SFRH/BD/99507/2014.

In project: Pedro Borrego (Pharmacy, Post-Doc). Molecular epidemiology and evolutionary dynamics of HIV-1,

HBV and HCV in Portuguese-speaking countries: improving clinical decisions and preventing new infections. Faculdade de Farmácia da Universidade Nova de Lisboa, Isabel Guedes de Mello (Universidade Federal de São Paulo, Brasil, Departamento de Medicina, Disciplina de Gastroenterologia. Laboratório de Hepatologia Molecular Aplicada.

International Masters in project Liliana Gomes. Hepatitis C in Portugal and lessons learned from the Scottish and the English

experiences. London School of Hygiene and Tropical Medicine. Supervisor: Martin McKee, Tutor: Neus Abrignes-Jaume. External Supervisor: Rui Marinho.

International PhD (Romenia) Rosu Alexandra Floriana, University and Medicine and Pharmacy of Craiova (Romenia). Convention

for bilateral cooperation for doctoral transnational mobility. Research Mobility Supervise rem colaboração com Prof. Tudorel Ciurea, scientific coordinator of the doctoral thesis. ”Chronic viral hepatitis C. Immunological profile and correlations with treatment response.

Ended Ricardo Ribeiro (Biomedical Engineering, in collaboration with Instituto Superior Técnico) Computer-

aided Diagnosis in Chronic Liver Disease based on Ultrasound Imaging). Public Presentation and approval in September 2013

Scientific Committee Centro de Investigação  Instituto de Direito Penal e Ciências Criminais. Faculdade de Direito da

Universidade de Lisboa. (Institute for Criminal Law and Criminal Sciences, Law School of Lisbon University).

Clinical Trials in 2013-2015Principal Investigator:

Clinical Study Protocol. M14–423 “An Open-Label, Multicenter Study to Evaluate Long-Term Outcomes With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (TOPAZ-I)”,

Clinical Study Protocol M13-098. A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 co-administered with Ribavirin (RBV) in treatment-experienced adults with genotype 1 chronic hepatitis C virus (HCV) infection (SAPPHIRE-II), 2013.

Clinical Study Protocol M13-961. A randomized, double-blind, controlled study to evaluate the efficacy and safety of the combination of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 with

2

and without Ribavirin (RBV) in treatment-naïve adults with genotype 1b chronic hepatitis C virus (HCV) infection (PEARL-III), 2013.

Clinical Study Protocol M13-389. A randomized, open-label, multicenter study to evaluate the safety and antiviral activity of the combination of ABT-450/Ritonavir/ABT-267 (ABT 450/r/ABT-267) and ABT-333 with and without ribavirin in treatment-experienced subjects with genotype 1b chronic hepatitis C virus (HCV) infection (PEARL-II), 2013.

Daiichi Sankyo/ArQule HCC (Study Number: ARQ197-A-U303): A Phase III, randomized, double-blind study of Tivantinib (ARQ 197) in subjects with MET diagnostic-High inoperable hepatocellular carcinoma (HCC) treated with one prior systemic therapy, 2014.

PEG BE Yond (GV28855). A phase IV, blood sample collection study for exploratory evaluation of the association of single nucleotide polymorphisms with treatment responses from subjects with HBE-antigen positive or negative chronic hepatitis B, who received therapy for hepatitis B with Peginterferon alfa-2a 40KD (PEG-IFN) +/- nucleos(t)ide analogue, March 2014.

Prospective study of biological samples for hepatocellular carcinoma collection. Biobank, Molecular Medicine Molecular, Lisbon, Portugal, March 2014.

Other Activities Interest in Health Management: taking courses (total 250 hours) in the last years (quality, audit, media

training, conflicts management, pharmacoeconomy, clinical trials, medical editing, communication, etc). Collaboration with the Portuguese Parliament in the “Resolution Project about Liver Diseases” approved

in January 2014 with 96% of the votes. Organization of the Biobank for hepatocellular carcinoma at Instituto de Medicina Molecular/Faculdade

de Medicina de Lisboa (2014). Member of the Steering Committee for a Strategic Consensus for the integrated management of hepatitis

C in Portugal, Catholic University of Portugal (2013-2014), support Gilead. Report edited by Universidade Católica Editora, Maio 2014http://consensohepatitec.pt/wp-content/uploads/Consenso-Hepatite-C.pdf

Member of the Steering Committee for a Programme Políticas de Saúde na Hepatite C – a Perspectiva portuguesa – based in the report from The Economist Intelligence Unit, support Janssen. (2013-2014).

Member of the group for the Portuguese Guidelines for hepatitis C treatment genotype 1 with protease inhibitors (2012).

Collaboration with Portuguese Government (Ministry of Internal Administration) with a scientific report about “The medical aspects of reducing the legal limit of blood alcohol concentration in drivers from 0.5 to 0.2 mg/ml.” (2001). Collaborating with Portuguese Ministry of Health (Direcção-Geral da Saúde): epidemiology of hepatitis C, hepatocellular carcinoma and hospital admissions for chronic liver disease.

Member of the Fiscal Council of Institute of Molecular Medicine, since 2006 to 2015. Member of the organizing committee of the 33rd Meeting of the European Association for the Study of

the Liver (Lisbon, 15-18 April 1998). Editor of the homepage (75.000 visitors). Member of the Portuguese Consensus Panel on Hepatitis C, 1999 and 2003.

Collaboration with Medical Students of Lisbon Faculty Association (Associação de Estudantes da Faculdade de Medicina de Lisboa): talks about alcohol, adult communication, invitation to liver meetings, students as associate editors of Acta Médica Portuguesa, collaboration in Twinning Project 2012, 2013, 2014 (visit of students from Turkey, United Kingdom, Netherlands), presentation of Golden Harry´s (2012), development of Acta Médica Portuguesa iPAD version, External Committee for Evaluation of AIMS meeting (Annual International Medical Students Meeting, 2014). Scientific Committee of AIMS meeting 2015 participation in the scientific speed dating. Presence in the “Health Journey of the Portuguese Parliament”, May 2014.

Collaboration with Portuguese Parliament Presence in the “Health Journey of the Portuguese Parliament”, 7 – 9 May 2014, with a team of 13

doctors, from seven hospitals, with the medical students association, SOS Hepatites (patient NGO). In representation of Portuguese Society of Gastroenterology. Performance of abdominal ultrasound, Fibroscan®, risk calculation and an infography for colon cancer. We have made 200 examinations.

Presence in the “Health Journey of the Portuguese Parliament”, May 2013. Performance Fibroscan® (41 examinations).

Participation in “Resolution for Liver Diseases” (hepatitis C, alcoholic liver disease, hepatocellular carcinoma, liver transplant), approved with 96% of votes in January 2014.

Collaboration with non-governmental organization President of Scientific Committee of “SOS Hepatites”, since 2010, with collaboration since 2005. Member of Scientific Committee of Portuguese Association of Hemophiliacs.

3

Member of Scientific Committee of Grupo Português Activistas sobre Tratamentos de VIH/SIDA (HIV), since 2007.

Comunidade Vida e Paz, Christmas event since 2012, with consultations and Fibroscan® for homeless people.

Besides scientific collaboration and advisory I usually attend patients referred form this organizations.

Main interest Hepatitis C: immunology, epidemiology, therapy, social issues. Hepatitis B: therapy. Hepatocellular carcinoma: epidemiology, therapy Alcohol, traffic accidents, liver disease, social issues, youn people. Medical Publishing and editing, four years as an editor-in-chief of a Web of Science/Pubmed indexed

medical journal. Health Management Medical teaching, medical pedagogy

Scientific Presentations: as first author: 505.

National Awards: nineteen (six as first author).

Scientific Organizations as the main organizer1. Encontro Nacional de Hepatologia (APEF), 1995.2. Reunião regional da APEF - hepatologia pediátrica, 1996.3. Curso de Gestão de Conflitos, 2008.4. 11ª Reunião Anual da Associação Portuguesa para o Estudo do Fígado, 2008.5. Curso ”Comunicação de Más Notícias”, 2008.6. Hepatites, Droga e Álcool, 2009.7. 12ª Reunião Anual da Associação Portuguesa para o Estudo do Fígado, 2009.8. I Curso Hepatites Víricas, 2010.9. Viral Hepatitis Prevention Board. Burden and Prevention of Viral Hepatitis in Portugal, 2010. 10. II Curso Hepatites Víricas, 2011.11. III Curso Hepatites Víricas, 2012.12. I Simpósio Acta Médica Portuguesa. Lisbon, Portuguese Medical Association. The innovation in

medical editing, 201213. IV Curso Hepatites Víricas, 2013.14. V Curso Hepatites Víricas, 2014.15. Care of Critical Patients in Gastroenterology, (Nursing School of S. Francisco das Misericórdias), 201316. II Simpósio Acta Médica Portuguesa, Lisbon, Portuguese Medical Association. Workshop Cochrane

(Christian Gluud, Dimitrinka Nikolova), Medical Imaging (Daniel Muller, New England Journal of Medicine), 2013.

17. Medical Writting in XX Jornadas de Pediatria, Hospital S. Maria, 2014.18. Member of the Scientific Committee and of the Organizing Committee with the Viral Hepatitis

Prevention Board in the organization of “Prevention and control of Viral Hepatitis in Brazil and Latin America” with the Ministry of Health of Brazil, CDD and PHAO/WHO and delegates from the 27 states of Brazil, Brasília, 19-21 April 2014.

19. III Simpósio Acta Médica Portuguesa, Lisbon, Portuguese Medical Association, November 2014.

Member of International Societies: European Association for Study of the Liver, American Association for the Study of Liver Diseases, International Liver Cancer Association, American College of Gastroenterology, International Association for the Study of the Liver, Sociedade Brasileira de Hepatologia.

Viral Hepatitis Prevention Board (2008 – 2015): Adviser of the Viral Hepatitis Prevention Board (WHO Collaborating Centre for the Prevention and Control of Viral Hepatitis). The November 2010 meeting took place in Portugal with the theme “Burden of viral hepatitis in Portugal”. This group includes 35 people from 17 countries, some leaders of WHO – hepatitis (Stefan Wiktor, Daniel Lavanchy), CDC (John Ward), European Liver Patients Association (Tatjiana Reic), ECDC from Sweden, Pierre Van Damme.

European Board of Gastroenterology and Hepatology (FEBGH)Fellowship since 2009.

United European Gastroenterology

4

Elected Member of General Assembly of United European Gastroenterology (26.1.2014-31.12.2017) with 22 votes (5th place in 14 candidates). UEG includes 56 member societies, 41 countries, 25.776 specialists. General Assembly has 61 members, 23 representing national societies from 20 countries. The UEG Week has 14.000 delegates from 125 countries.

Reviewer of abstracts for UEG Week 2015.

African Countries, Brazil Collaboration and network with colleagues from Angola and Mozambique. Brazil – since 2007 strong network with hepatologists from Brazil. Besides the organization and

participation in medical meetings in the two countries, I have received to work in our Department mainly in the Fibroscan® setting 15 doctors from Brazil (Salvador, S. Paulo, Amazonia).

International Publications: 68 indexed in Pubmed/Medline (Marinho RT or Marinho R)New England Journal Medicine, American Journal Medicine, Journal Gastrointestinal Liver Dis, Enferm Infecc Microbiol Cli, Journal Clinical Virology, Revista Esp Enferm Digestivas, European Journal of Gastroenterology Hepatology, Hepatogastroenterology, Journal Clin Gastroenterol, Digestive Diseases Sciences, Journal Viral Hepatitis, Liver International, World Journal Gastroenterology, Gastroenterol Clinique Biol, J Gastroenterol Hepatol, Acta Médica Portuguesa, IEEE Trans Biomed Eng, Med Phys, BMJ Case Reports, Annals of Oncology, Endoscopy. Letters, images: Gastroenterology, Hepatology, Liver Transplantation, Journal of Hepatology.

Last Publications Dicas para Escrever um Título. Tips for a Title. Donato H. Marinho RT. Acta Med Port 2015;28:269-

270. Dez Conquistas nos 35 anos do Serviço Nacional de Saúde Português (1979 - 2015): Pensar Passado

e Projetar Futuro. Ten Achievements for 35 years of the Portuguese National Health Service (1979-2015): Looking Back, Planning the Future. Pestana PC, Marinho RT. Acta Med Port 2015.;28):135-137.

Chronic hepatitis and other liver disease. Pierre Van Damme, Tinne Lernout, Koen Van Herck, Rui T Marinho, Raymundo Parana, and Daniel Shouval. .Chapter 8, section 8.16, p. 1175-1191; in Oxord Textbook of Global Public Health, 6th Edition, Eds: Roger Detels, Martin Gulliford, Quarraisha Abdool Karim, Chorh Chuan Tan, Oxford University Press, 2015.

Marinho RT, De-Sousa C, Donato H, Massano J, Crespo J. [Let's Go Publishing!]. Acta Med Port. 2014;27:673-4.

Marinho RT, Donato H. [Welcome aboard the acta medica portuguesa, welcome to the first international division!]. Acta Med Port 2014;27:533-4.

Ferreira A, Marinho RT. Risky business — the real life of the unresolved HCV therapy. Gastroenterology 2014; Gastroenterology 2014;147:1185–1187. Impact Factor 13,926.

Marinho R. 'The last coachman', the trio of risk factors: alcohol, tobacco and traffic accidents. Acta Med Port 2014;27:406-7. Impact Factor 51,658.

Ferenci P, Bernstein D, Lalezari J, Cohen D, Luo Y, Cooper C, Tam E, Marinho RT, et al. ABT-450/r-Ombitasvir and Dasabuvir with or without Ribavirin for HCV. N Engl J Med. 2014 May 4. [Epub ahead of print] PubMed PMID: 24795200. Impact Factor 51,658.

Travassos AR, Soares-de-Almeida L, Marinho RT. A Medicina na obra de Amadeo de Souza-Cardoso Acta Med Port 2014;27:277-280. Impact Factor 0,281.

Zeuzem S, Jacobson I, Baykal T, Marinho RT, Poordad F, Bourlière M, et al. Retreatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin. N Engl J Med 2014;370:1604-14. DOI: 10.1056/NEJMoa1401561. Impact Factor 51,658.

Bruggmann P, Berg T, Ovrehus AL, Moreno C, Brandão Mello CE, Roudot-Thoraval, F, Marinho RT, et al. Historical epidemiology of hepatitis C virus, (HCV) in selected countries. J Viral Hepat 2014;21 Suppl 1:5-33. Impact Factor 3,082.

Razavi H, Waked I, Sarrazin C, Myers RP, Idilman R, Calinas F, (…) Marinho RT, (…) et al. Present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm. J Viral Hepat 2014;21 Suppl 1:34-59. Impact Factor 3,082.

Wedemeyer H, Duberg AS, Buti M, Rosenberg WM, Frankova S, Esmat G, (…) Marinho RT,(…), et al. Strategies to manage hepatitis C virus (HCV) disease burden. J Viral Hepat 2014;21 Suppl 1:60-89. Impact Factor 3,082.

Marinho RT, Duarte H, Nunes J, Ferreira A, Giria J, Velosa J. The burden of alcoholism in fiteen years of liver cirrhosis hospital admissions in Portugal. Liver Int. 2014 Apr 22. doi: 10.1111/liv.12569. [Epub ahead of print] PubMed PMID: 24750642. Impact Factor 3,87.

Marinho RT, Vitor S, Velosa J. Benefits of curing hepatitis C infection. J Gastrointest Liver Dis, 2014;23:85-90. Impact Factor 1,885.

5

Marinho RT, Donato H, Fernandez-Llimos F, Massano J, Silva JM, Almeida M, Carona Carvalho J, Villanueva T, Eurico Fonseca J. [Think Tank: Strategic Report on the Scientific Biomedical Publication in Portugal]. Acta Med Port 2014;27:1-3. Impact Factor 0,281.

Ribeiro R, Marinho R, Sanches J. An ultrasound based computer-aided diagnosis tool for steatosis detection. IEEE J Biomed Health Inform 2013 Oct 7. Impact Factor 1,97.

Marinho RT, Barreira D. Hepatitis C, Stigma and cure. World Journal of Gastroenterology 2013; 19:6703-6709. Impact Factor 2,547.

Donato H, Marinho RT. [How to Do an Effective Literature Search? The Use of Push and Pull Strategies]. Acta Med Port 2013;26:471-475. Impact Factor 0,281.

Dufour JF, Bargellini I, De Maria N, De Simone P, Goulis I, Marinho RT. Intermediate hepatocellular carcinoma: current treatments and future perspectives. Ann Oncol 2013;24 Suppl 2:ii24-9. Impact Factor 7,38.

International Editorial Board: World Journal Gastroenterology (2010-2017), Journal of Gastrointestinal and Liver Diseases (since

2010), Hepatitis Monthly (since 2011), Case Reports in Hepatology (since 2011), Experimental & Clinical Hepatology, Research Journal Infectious Diseases (since 2013), Edorium Journal of Hepatology (since 2013), World Journal of Hepatology (2013-2017), Clinical Hepatology and Hepatitis Reports (2014)

Reviewer for 23 International Journals – 72 papers: British Medical Journal (four papers), PLOS Medicine, Annals of Gastroenterology, Journal Viral Hepatitis, Vaccine, Alcohol and Alcoholism, Journal Medical Virology, Med Sci Monit, Int J Immunopathol Pharmacology, European Journal of Gastroenterology and Hepatology (five papers), World Journal Gastroenterology, Hepatitis Monthly, Case Reports in Hepatology, BMJ Case Reports, Journal Infect Public Health, World Journal Oncology, Liver International, World Journal Hepatology, Therapeutic Advances in Gastroenterology, World Journal of Transplantation, Revista da Sociedade Brasileira de Medicina Tropical, Human Vaccines and Immunotherapeutics, International Journal of Drug Policy.

Hobbies:Running 10km and half-marathons, reading (painting, classic philosophy – the stoics, management – Peter Drucker, Harvard Business Reviews, Brian Tracy, etc), music (classic jazz, Irish folk, traditional Andean music, Keith Jarrett), Ted Talks.

Family:Luísa (endocrinologist, Hospital Garcia de Orta, coordinator of Endocrinology Unit of Hospital dos Lusíadas), João Pedro (European jurist, Hitachi, Brussels, Belgium), Margarida (economist, Bank of Portugal).

Work address:Serviço de Gastrenterologia e Hepatologia, Hospital S. Maria, Av. Prof. Egas Moniz, 1600 LISBOA, Portugal, Phone: +351 916 98 40 40, E-mail: ruitatomarinho@sapo.pt

Linkedin® http://www.linkedin.com/pub/rui-tato-marinho-md-phd/14/667/a2b

Lisbon, July 2015

6